

MONARCH and ADMIRAL Interim Analyses: Open-label, Phase 1/2a Studies in US and UK Investigating STK-001, an Antisense Oligonucleotide (ASO), in Children and Adolescents with Dravet Syndrome (DS) Helen Cross¹, Linda Laux², Joseph Sullivan³, Archana Desurkar⁴, Colin Roberts⁵, John Schreiber⁶, Scott Perry⁷, Orrin Devinsky⁸, Matt Lallas⁹, Steven Phillips¹⁰, Andreas Brunklaus¹¹

Carrie Condon¹², Charlene Brathwaite¹², James Stutely¹², Jessie Lynch¹², Fei Wang¹², Kimberly A. Parkerson¹², Barry Ticho¹² ¹Great Ormond Street Hospital for Children; ²Lurie Children's Hospital Chicago, ³University of California San Francisco; ⁴Sheffield Children's; ⁵Oregon Health Sciences University; ⁶Children's National Hospital; ⁷Cook Children's; ⁸New York University Langone Health; ⁹Neuro Network Partners; ¹⁰Mary Bridge Children's; ¹¹Royal Hospital for Children; ¹²Stoke Therapeutics

BACKGROUND


- DS is a severe and progressive genetic epilepsy characterized by frequent, prolonged, and refractory seizures, typically beginning within the first year (y) of life
- Available therapies do not adequately control seizures in 90% of patients with DS, and they do not address other comorbidities, including intellectual disability, ataxia/motor abnormalities, behavioral problems, speech impairment, sleep disturbances, and a high risk for sudden unexpected death
- Disease complications often contribute to a poor quality of life for patients and their caregivers
- In approximately 85% of cases, DS is caused by spontaneous, heterozygous loss of function mutations in the SCN1A gene, which encodes the voltage-gated sodium channel type 1 α subunit (Na_v1.1) protein
- Upregulating Na_v1.1 protein may restore functioning neurons and prevent seizures and reduce non-seizure related comorbidities in DS


MECHANISM OF ACTION

- The proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform aims to increase protein production from the healthy gene
- In DS, patients have one functional gene (wild type) copy and one mutated copy, resulting in half as much protein as needed to maintain health
- STK-001 is an investigational proprietary ASO designed to upregulate $Na_v 1.1$ protein expression by leveraging the non-mutant (wild type) copy of SCN1A to restore physiological Nav1.1 protein levels
- SCN1A is transcribed into pre-messenger RNA (pre-mRNA) that is spliced to generate productive mRNA (which is translated into Na_V1.1 protein) and non-productive mRNA due to the inclusion of an exon that leads to nonsense-mediated mRNA decay (NMD). TANGO ASOs bind to specific stretches of SCN1A pre-mRNA to prevent the inclusion of the non-productive exon thereby increasing productive mRNA
- Increased level of productive mRNA from the functional gene copy increases Na_v1.1 protein production restoring it to near normal levels
- STK-001 may be the first disease-modifying therapy to address the genetic cause of DS by upregulating $Na_{v}1.1$ protein levels

ACKNOWLEDGEMENTS

Studies are supported by Stoke Therapeutics, and we thank investigators, health care providers, research staff, patients, and caregivers who participated.






D	Ε	Μ	0

Mean	(
Media	n

	er	na	le
M	a	e	

≥3

- mg/dose



SAFETY							
Patients n (%)	2-12y n=40	13-18y n=34	Total N=74	TEAEs in >10% by Preferred Termn (%)Post lumbar puncture syndrome19 (25.7)			
TEAEs	38 (95.0)	32 (94.1)	70 (94.6)	Vomiting	17 (23.0)		
TEAEs related to study drug	9 (22.5)	15 (44.1)	24 (32.4)	Seizure	16 (21.6)		
≥Grade 3 TEAEs	7 (17.5)	5 (14.7)	12 (16.2)	Pyrexia Upper respiratory tract infection	14 (18.9) 12 (16.2)		
≥Grade 3 TEAEs related to study drug	0	1 (2.94)	1 (1.35)	Irritability Contusion	11 (14.9)		
Serious TEAEs	7 (17.5)	8 (23.5)	15 (20.3)	CSF protein increased	10 (13.5)		
Serious TEAEs related to study drug	0	1 (2.94)	1 (1.35)	Rhinorrhea Diarrhea	10 (13.5) 9 (12.2)		
TEAEs leading to death	0	1 (2.94)	1 (1.35)	Nasopharyngitis	9 (12.2)		
Safety data cutoffs: 12Apr2023 (ADMIRAL); 13Apr2023 (MONARCH) 8 (10.8							

- Most treatment-emergent AEs (TEAEs) were mild to moderate; 1 fatal event (SUDEP) not related to study drug 24 (32.4%) patients with TEAE's related to study drug

